Prospective Echocardiographic Assessment of Androgenic-Anabolic Steroids Effects on Cardiac Structure and Function in Strength Athletes

Abstract

Since the abuse of androgenic-anabolic steroids (AAS) has been associated with the occurrence of serious cardiovascular disease in young athletes, we performed two studies to investigate the effects of short-term AAS administration on heart structure and function in experienced male strength athletes, with special reference to dose and duration of drug abuse. In Study 1 the effects of AAS were assessed in 17 experienced male strength athletes (age 31 ± 7 y) who self-administered AAS for 8 or 12 - 16 weeks and in 15 non-using strength athletes (age 33 ± 5 y) in a non-blinded design. In Study 2 the effects of administration of nandrolone decanoate (200 mg/wk i. m.) for eight weeks were investigated in 16 bodybuilders in a randomised double blind, placebo controlled design. In all subjects M-mode and two-dimensional Doppler-echocardiography were performed at baseline and after 8 weeks AAS administration. In the athletes of Study 1 who used AAS for 12 - 16 weeks a third echocardiogram was also made at the end of the AAS administration period. Echocardiographic examinations included the determination of the aortic diameter (AD), left atrium diameter (LA), left ventricular end diastolic diameter (LVEDD), interventricular septum thickness (IVS), posterior wall end diastolic wall thickness (PWEDWT), left ventricular mass (LVM), left ventricular mass index (LVMI), ejection fraction (EF) and right ventricular diameter (RVD). For assessment of the diastolic function measurements of E and A peak velocities and calculation of E/A ratio were used. In addition, acceleration and deceleration times of the E-top (ATM and DT, respectively) were determined. For evaluation of factors associated with stroke volume the aorta peak flow (AV) and left ventricular ejection times (LVET) were determined. In Study 1 eight weeks AAS self-administration did not result in changes of blood pressure or cardiac size and function. Additionally, duration of AAS self-administration did not have any impact on these parameters. Study 2 revealed that eight weeks administration of nandrolone decanoate did not induce significant alterations in blood pressure and heart morphology and function. Short-term administration of AAS for periods up to 16 weeks did not lead to detectable echocardiographic alterations of heart morphology and systolic and diastolic function in experienced strength athletes. The administration regimen used nor the length of AAS abuse did influence the results. Moreover, it is concluded that echocardiographic evaluation may provide incomplete assessment of the actual cardiac condition in AAS users since it is not sensitive enough to detect alterations at the cellular level. Nevertheless, from the present study no conclusions can be drawn of the cardiotoxic effects of long term AAS abuse.

Androgenic-anabolic steroids - nandrolone decanoate - echocardiography - blood pressure - heart morphology - heart function - doping

References

• 1 Appell HJ, Heller-Umpfenbach B, Feraudi M, Weicker H. Ultrastructural and morphometric investigations on the effects of training and administration of anabolic steroids on the myocardium of guinea pigs.  Int J Sports Med. 1983;  4 268-274
• 2 Bahrke M S, Yesalis C R, Wright J E. Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids. An update.  Sports Med. 1996;  22 367-390
• 3 Behrendt H. Effect of anabolic steroids on rat heart muscle cells. I. Intermediate filaments.  Cell Tissue Res. 1977;  180 303-315
• 4 Behrendt H, Boffin H. Myocardial cell lesions caused by an anabolic hormone.  Cell Tissue Res. 1977;  181 423-426
• 5 Brown B S, Pilch A H. The effects of exercise and dianabol upon selected performances and physiological parameters in the male rat.  Med Sci Sports. 1972;  4 159-165
• 6 de Piccoli B, Giada F, Benettin A, Sartori F, Piccolo E. Anabolic steroid use in body builders: an echocardiographic study of left ventricle morphology and function.  Int J Sports Med. 1991;  12 408-412
• 7 Dickerman R D, Schaller F, Zachariah N Y, McConathy W J. Left ventricular size and function in elite bodybuilders using anabolic steroids.  Clin J Sport Med. 1997;  7 90-93
• 8 Ferenchick G S, Adelman S. Myocardial infarction associated with anabolic steroid use in a previously healthy 37-year-old weight lifter.  Am Heart J. 1992;  124 507-508
• 9 Friedl K E. Effects of anabolic steroids on physical health. In: Yesalis CE (ed) Anabolic Steroids in Sport and Exercise. Champaign; Human Kinetics 2000 2nd ed: 175-224
• 10 Hartgens F, Kuipers H, Wijnen J, Keizer H A. Body composition, cardiovascular risk factors and liver function in long term androgenic-anabolic steroids using bodybuilders three months after drug withdrawal.  Int J Sports Med. 1996;  17 429-433
• 11 Huie M J. An acute myocardial infarction occurring in an anabolic steroid user (case study).  Med Sci Sports Exerc. 1994;  26 408-413
• 12 Ishak K G, Zimmerman H J. Hepatotoxic effects of the anabolic/androgenic steroids.  Semin Liver Dis. 1987;  7 230-236
• 13 Kennedy M C, Lawrence C. Anabolic steroid abuse and cardiac death.  Med J Aust. 1993;  158 346-348
• 14 Koert A, van Kleij R. Handel in doping. Nieuwegein; Arko Uitgeverij 1998
• 15 Kutscher E C, Lund B C, Perry P J. Anabolic steroids: a review for the clinician.  Sports Med. 2002;  32 285-296
• 16 McKillop G, Todd IC, Ballantyne D. Increased left ventricular mass in a bodybuilder using anabolic steroids.  Br J Sports Med. 1986;  20 151-152
• 17 Melchert R B, Welder A A. Cardiovascular effects of androgenic-anabolic steroids. Med Sci.  Sports Exerc. 1995;  27 1252-1262
• 18 Mochizucki R M, Richter K J. Cardiomyopathy and cerebrovascular accident associated with anabolic-androgenic steroid use.  Physician Sportsmed. 1988;  16 109-114
• 19 Moore L G, McMurtry I F, Reeves J T. Effects of sex hormones on cardiovascular and hematologic responses to chronic hypoxia in rats.  Proc Soc Exp Biol Med. 1978;  158 658-662
• 20 Morano I, Gerstner J, Ruegg J C, Ganten U, Ganten D, Vosberg V P. Regulation of myosin heavy chain expression in the hearts of hypertensive rats by testosterone.  Circ Res. 1990;  66 1585-1590
• 21 Nieminen M S, Ramo M P, Viitasalo M, Heikkila P, Karjalainen J, Mantysaari M, Heikkila J. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters.  Eur Heart J. 1996;  17 1576-1583
• 22 Palatini P, Giada F, Garavelli G, Sinisi F, Mario L, Michieletto M, Baldo E G. Cardiovascular effects of anabolic steroids in weight-trained subjects.  J Clin Pharmacol. 1996;  36 1132-1140
• 23 Pärssinen M, Seppala T. Steroid use and long-term health risks in former athletes.  Sports Med. 2002;  32 83-94
• 24 Pelliccia A, Maron B J. Outer limits of the athlete's heart, the effect of gender, and relevance to the differential diagnosis with primary cardiac diseases.  Cardiol Clin. 1997;  15 381-396
• 25 Pesola M K. Reversibility of the haemodynamic effects of anabolic steroids in rats.  Eur J Appl Physiol. 1988;  58 125-131
• 26 Ramo P, Kettunen R, Hirvonen L. The effects of anabolic steroids and endurance training on systolic time intervals in the dog.  Acta Physiol Scand. 1987;  129 543-548
• 27 Sachtleben T R, Berg K E, Elias B A, Cheatham J P, Felix G L, Hofschire P J. The effects of anabolic steroids on myocardial structure and cardiovascular fitness.  Med Sci Sports Exerc. 1993;  25 1240-1245
• 28 Salke R C, Rowland T W, Burke E J. Left ventricular size and function in body builders using anabolic steroids.  Med Sci Sports Exerc. 1985;  17 701-704
• 29 Spataro A, Caselli G, Pelliccia A, Biffi A, Iranquilli C, Fernando F, Marcello G. Anabolic steroids do not increase left ventricular mass index in well trained athletes (abstract).  Med Sci Sports Exerc. 1992;  24 S29
• 30 Spirito P, Pelliccia A, Proschan M A, Granata M, Spataro A, Bellone P, Caselli G, Biffi A, Vecchio C, Maron B J. Morphology of the “athlete's heart” assessed by echocardiography in 947 elite athletes representing 27 sports.  Am J Cardiol. 1994;  74 802-806
• 31 Sullivan M L, Martinez C M, Gallagher E J. Atrial fibrillation and anabolic steroids.  J Emerg Med. 1999;  17 851-857
• 32 Tagarakis C V, Bloch W, Hartmann G, Hollmann W, Addicks K. Anabolic steroids impair the exercise-induced growth of the cardiac capillary bed.  Int J Sports Med. 2000;  21 412-418
• 33 Tagarakis C V, Bloch W, Hartmann G, Hollmann W, Addicks K. Testosterone-propionate impairs the response of the cardiac capillary bed to exercise.  Med Sci Sports Exerc. 2000;  32 946-953
• 34 Thomas L R, Douglas P S. Echocardiographic findings in athletes. In: Thompson PD (ed) Exercise and Sports Cardiology. New York; McGraw-Hill 2001: 43-70
• 35 Thompson P D, Sadaniantz A, Cullinane E M, Bodziony K S, Catlin D H, Torek B G, Douglas P S. Left ventricular function is not impaired in weight-lifters who use anabolic steroids.  J Am Coll Cardiol. 1992;  19 278-282
• 36 Urhausen A, Holpes R, Kindermann W. One- and two-dimensional echocardiography in bodybuilders using anabolic steroids.  Eur J Appl Physiol. 1989;  58 633-640
• 37 Yeater R, Reed C, Ullrich I, Morise A, Borsch M. Resistance trained athletes using or not using anabolic steroids compared to runners: Effects on cardiorespiratory variables, body composition, and plasma lipids.  Br J Sports Med. 1996;  30 11-14
• 38 Yesalis C. Anabolic steroids in sport and exercise. Champaign, IL; Human Kinetics 2000 2nd ed
• 39 Zuliani U, Bernardini B, Catapano A, Campana M, Cerioli G, Spattini M. Effects of anabolic steroids, testosterone, and HGH on blood lipids and echocardiographic parameters in body builders.  Int J Sports Med. 1989;  10 62-66